This study is testing an investigational drug called Frevecitinib (KN-002) delivered through a dry powder inhaler (DPI) for people with severe asthma that isn't well-controlled by their current medications. Researchers want to see how effective and safe Frevecitinib is compared to a placebo (an inactive substance). You might be able to join if you are between 18 and 75 years old, have a body mass index (BMI) between 18 and 40, and have had a doctor diagnose your asthma at least 12 months ago. The main goal is to measure your lung function (Pre-BD FEV1) after 12 weeks of treatment to see if Frevecitinib helps improve it.

Study design

This is a Phase 2, randomized, double-blind, placebo-controlled study involving about 512 participants. It will compare three different doses of Frevecitinib to a placebo.

What's involved

You would receive treatment for 12 weeks. Specific details about visits, procedures, or tests are not provided in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at Week 12, suggesting the main treatment period is 12 weeks. Further follow-up is not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.